Article info
Commentary
Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
- Correspondence to Dr Ruben Hernaez, Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA; ruben.hernaez{at}bcm.edu
Citation
Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
Publication history
- Received March 18, 2022
- Accepted April 11, 2022
- First published April 26, 2022.
Online issue publication
December 07, 2022
Article Versions
- Previous version (26 April 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.